*Category 2A: Based upon lower-level evidence; compared to Category 1; there is uniform NCCN consensus that the intervention is appropriate.1
†Lower-risk MF is defined as low or intermediate-1 risk based on DIPSS, DIPSS-Plus, and MYSEC-PM, low or intermediate risk based on MIPSS-70 (threshold of ≤3 prognostic variable points), and very low, low, or intermediate risk based on MIPSS-70+ (version 2.0; threshold of ≤3 prognostic variable points).1
†In patients who are not transplant candidates.
Jakafi is indicated for treatment of intermediate or high-risk MF, including primary MF, post–polycythemia vera MF and post–essential thrombocythemia MF in adults.
‡Estimated total patients treated with commercially available Jakafi in the US since 2011.2
See Prescribing Information for FDA-approved indications.
- Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Myeloproliferative Neoplasms V.1.2020. © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed September 4, 2019. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
- Data on file. Incyte Corporation. Wilmington, DE.